Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Osteoporosis and Osteonecrosis in Children With Leukemia
NCT02632903Phase 2Withdrawn
- Sponsor
- Children's Hospital of Eastern Ontario
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in osteoporosis, osteonecrosis, sponsored by Children's Hospital of Eastern Ontario. Planned start Oct 2016; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisosteonecrosis
Beyond the preview
Go deeper on NCT02632903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632903.